Description: Erytech Pharma SA, also known as ERYTECH Pharma, is a France-based biopharmaceutical company developing medicinal products mainly in oncology, hematology and immunology fields of business. The Company offers ESY-ASP (GRASPA), a medicinal product consisting of L-Asparaginase entrapped into human homologous red blood cells. The product is used for treatment of Acute Lymphoblastic Leukemia (ALL), a childhood cancer. The Company's technology is based on the use of human red blood cells (RBCs) to improve the pharmacokinetic (PK) and pharmacodynamic (PD) properties of therapeutic enzymes, for instance asparaginase. The enzyme can destroy asparagine and deprive cancer cells of an important nutrient for these cells, resulting in their death. The Company's subsidiary is Erytech Pharma, Inc in the USA which legal existence began in April 9, 2014.
Home Page: www.erytech.com
ERYP Technical Analysis
60 Avenue Rockefeller
Lyon,
69008
France
Phone:
33 4 78 74 44 38
Officers
| Name | Title |
|---|---|
| Mr. Gil Beyen BVBA | CEO & Director |
| Mr. Eric Soyer Ph.D. | Deputy GM, CFO & COO |
| Dr. Jérôme Bailly Pharm.D. | Deputy GM of Operations, Chief Quality Officer & Qualified Person |
| Naomi Eichenbaum | Director Investor Relations |
| Mr. Brian Schwab | Chief Legal Officer & Gen. Counsel |
| Ms. Anne-Cécile Fumey | HR Director |
| Dr. Iman El-Hariry M.D., Ph.D. | Chief Medical Officer |
| Dr. Philip L. Lorenzi | Consultant & Member of Scientific Board |
| Prof. Eric Raymond M.D., Ph.D. | Consultant & Member of Scientific Board |
| Dr. Bridget Bax | Consultant & Member of Scientific Board |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6542 |
| Price-to-Sales TTM: | 7.5782 |
| IPO Date: | 2016-07-05 |
| Fiscal Year End: | December |
| Full Time Employees: | 181 |